Prescribing psychostimulants for persons with schizophrenia spectrum disorders and attention-deficit hyperactivity disorder: practice with little guidance

Psychostimulant prescribing for individuals with comorbid attention-deficit hyperactivity disorder and schizophrenia spectrum disorders appears increasingly common despite limited evidence to guide the practice. This commentary highlights diagnostic and treatment challenges, critiques the current evidence base and argues for cautious prescribing, greater attention to substance use and the development of pragmatic clinical guidance.